Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease.

Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease.
复制标题

脂质运载蛋白2刺激慢性肾病患者骨成纤维细胞生长因子23的产生。

DOI:
10.1038/s41413-021-00154-0
复制
发表时间:
2021-08-02
期刊:
影响因子:
12.7
通讯作者:
David V
David V
中科院分区:
医学1区
文献类型:
--
作者:
Courbon G;Francis C;Gerber C;Neuburg S;Wang X;Lynch E;Isakova T;Babitt JL;Wolf M;Martin A;David V

文献摘要

参考文献

被引文献

相似文献

Bone-produced fibroblast growth factor 23 (FGF23) increases in response to inflammation and iron deficiency and contributes to cardiovascular mortality in chronic kidney disease (CKD). Neutrophil gelatinase-associated lipocalin (NGAL or lipocalin 2; LCN2 the murine homolog) is a pro-inflammatory and iron-shuttling molecule that is secreted in response to kidney injury and may promote CKD progression. We investigated bone FGF23 regulation by circulating LCN2. At 23 weeks, Col4a3KO mice showed impaired kidney function, increased levels of kidney and serum LCN2, increased bone and serum FGF23, anemia, and left ventricular hypertrophy (LVH). Deletion of Lcn2 in CKD mice did not improve kidney function or anemia but prevented the development of LVH and improved survival in association with marked reductions in serum FGF23. Lcn2 deletion specifically prevented FGF23 elevations in response to inflammation, but not iron deficiency or phosphate, and administration of LCN2 increased serum FGF23 in healthy and CKD mice by stimulating Fgf23 transcription via activation of cAMP-mediated signaling in bone cells. These results show that kidney-produced LCN2 is an important mediator of increased FGF23 production by bone in response to inflammation and in CKD. LCN2 inhibition might represent a potential therapeutic approach to lower FGF23 and improve outcomes in CKD.
DOI: 10.1016/j.bbcan.2012.03.008
发表时间: 2012-08
影响因子: 11.2
作者:
Chakraborty, Subhankar;Kaur, Sukhwinder;Guha, Sushovan;Batra, Surinder K.
通讯作者: Batra, Surinder K.
DOI: 10.1056/nejmoa0706130
发表时间: 2008-08-07
期刊: The New England journal of medicine
影响因子: --
作者:
Gutiérrez OM;Mannstadt M;Isakova T;Rauh-Hain JA;Tamez H;Shah A;Smith K;Lee H;Thadhani R;Jüppner H;Wolf M
通讯作者: Wolf M
DOI: 10.1371/journal.pone.0044328
发表时间: 2012
期刊: PloS one
影响因子: 3.7
作者:
Chassaing B;Srinivasan G;Delgado MA;Young AN;Gewirtz AT;Vijay-Kumar M
通讯作者: Vijay-Kumar M
DOI: 10.1016/j.kint.2019.07.026
发表时间: 2019-12-01
影响因子: 19.6
作者:
Francis, Connor;Courbon, Guillaume;David, Valentin
通讯作者: David, Valentin
DOI: 10.1073/pnas.0510847103
发表时间: 2006-02-07
影响因子: 11.1
作者:
Berger, T;Togawa, A;Mak, TW
通讯作者: Mak, TW